Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) EBIT: 2022-2025

Historic EBIT for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$885,260.

  • Addex Therapeutics' EBIT rose 10.98% to -$885,260 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.8 million, marking a year-over-year increase of 21.92%. This contributed to the annual value of -$3.1 million for FY2024, which is 25.40% down from last year.
  • Addex Therapeutics' EBIT amounted to -$885,260 in Q2 2025, which was down 31.28% from -$674,315 recorded in Q1 2025.
  • Addex Therapeutics' EBIT's 5-year high stood at -$397,496 during Q1 2023, with a 5-year trough of -$21.3 million in Q4 2022.
  • For the 3-year period, Addex Therapeutics' EBIT averaged around -$958,483, with its median value being -$835,549 (2023).
  • Per our database at Business Quant, Addex Therapeutics' EBIT surged by 96.14% in 2023 and then slumped by 127.15% in 2024.
  • Quarterly analysis of 4 years shows Addex Therapeutics' EBIT stood at -$21.3 million in 2022, then skyrocketed by 96.14% to -$822,846 in 2023, then spiked by 38.18% to -$508,692 in 2024, then rose by 10.98% to -$885,260 in 2025.
  • Its last three reported values are -$885,260 in Q2 2025, -$674,315 for Q1 2025, and -$508,692 during Q4 2024.